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Abstract
Background: Levosimendan has pharmacologic and hemodynamic advantages over conventional intravenous
inotropic agents. It has been used mainly as a rescue drug in the pediatric intensive care unit or in the operating
room. We present the largest single-center experience of levosimendan in children.
Methods: Retrospective analysis of all children who received levosimendan infusions between July 5, 2001 and
July 4, 2010 in a pediatric intensive care unit. The results of a questionnaire for physicians (anesthesiologist/
intensivists, cardiologists and cardiac surgeons) concerning their clinical perceptions of levosimendan are evaluated
Results: During the study period a total of 484 infusions were delivered to 293 patients 53% of whom were male.
The median age of the patients was 0.4 years (4 hours-21.1 years) at the time of levosimendan administration.
A majority of levosimendan infusions were administered to children who were undergoing cardiac surgery (72%),
14% to children with cardiomyopathy and 14% to children with cardiac failure. Eighty-nine out of the 293 patients
(30.4%) received repeated doses of levosimendan (up to 11 infusions). The most common indication for the use of
levosimendan (94%) was when the other inotropic agents were insufficient to maintain stable hemodynamics.
Levosimendan was especially used in children with cardiomyopathy (100%) or with low cardiac output syndrome
(94%). A majority (89%) of the respondents believed that levosimendan administration postponed the need for
mechanical assist devices in some children with cardiomyopathy. Moreover, 44% of respondents thought that the
mechanical support was totally avoided in some patients undergoing cardiac surgery after receiving levosimendan.
Conclusion: Levosimendan is widely used in our institution and many physicians believe that its use could decrease
the need for mechanical support in children undergoing cardiac surgery or in children with decompensated heart
failure. However, there is a lack of good empirical evidence in children to support this perception.
Background
Levosimendan was developed for the treatment of decom-
pensated heart failure in situations for which conventional
therapy is not sufficient [1]. Levosimendan acts indepen-
dently of b-adrenergic receptors and cyclic adenosine
monophosphate (cAMP). Therefore it has pharmacologic
and hemodynamic advantages over conventional intrave-
nous inotropic agents [1,2]. It exerts its effect mainly
through two different mechanisms. The first mechanism is
by calcium sensitization of the contractile proteins in the
cardiomyocytes, which leads to increased contractility of
the heart [1,2]. The second mechanism opens the adeno-
sine triphosphate-sensitive potassium channels on vascular
smooth muscle, which causes coronary and peripheral
vasodilatation [1,2].
Levosimendan has a short half-life of approximately
one hour but its action has a fast onset and long-lasting
due to the active metabolite OR-1896 [2,3]. The maxi-
mum concentration of OR-1896 can be detected two
days after the 24-hour levosimendan infusion has
stopped, and its elimination half-life is 70-80 hours in
patients with heart failure [2].
Levosimendan appears to be efficacious and safe for
children with acute heart failure or children who are
undergoing cardiac surgery [3-11]. The number of chil-
dren in the retrospective and mainly observational studies
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patients [3,11]. Levosimendan has been used “off-label” as
a rescue drug in the pediatric intensive care unit (PICU)
or in the operating room (OR), because there are no offi-
cial indications for its use in patients under 18-years of
age to date.
In our institution levosimendan has been used in chil-
dren with decompensated heart failure and in children
undergoing cardiac surgery since 2001. The aim of this
review is to present retrospective data on levosimendan
administration and physicians surveyed for their percep-
tions about levosimendan’s efficacy and safety.
Methods
This is a retrospective analysis of data obtained from the
patients who received levosimendan infusion between July
5, 2001 and July 4, 2010 in the PICU of Children’s Hospi-
tal of Helsinki University Central Hospital. The Children’s
Hospital is a tertiary care teaching hospital responsible for
the care of all paediatric patients, in Finland (population
5.4 million) who inter alia require open-heart surgery and
transplantation.. This study was approved by the Ethics
Committee of Helsinki University Central Hospital.
Information regarding the levosimendan administration
was collected from the anaesthesia records and the inten-
sive care database (Centricity Critical Care Clinisoft; GE
Healthcare, Helsinki, Finland). The patients who received
levosimendan were classified into one of three groups
namely: cardiac surgery, cardiomyopathy and cardiac fail-
ure. The cardiac surgery group included patients to whom
levosimendan infusions were administered pre- peri or
postoperative during the same PICU admission in which
they had surgery. The cardiac failure group comprised
patients with decompensated cardiac failure who had not
been operated on during the PICU admission. These
patients also had cardiac failure whose etiology was exclu-
sive of cardiomyopathy. The third group consisted of chil-
dren with dilated cardiomyopathy, who had been admitted
to the PICU because of acute or chronic heart failure to
receive a repeated dose of levosimendan. Cardiomyopathy
patients on a left sided mechanical assist device (Berlin
Heart) who received levosimendan to support the right
ventricle, or had cardiac transplantion during the PICU
admission were also included in the cardiomyopathy group.
Each patient was included in only one of the three
patient groups in any one of the nine study years. There-
fore, a patient who had cardiac surgery and was re-
admitted to the PICU during that same year was still
considered to be a surgical patient. However, if a child
was admitted to the PICU several times over different
years, it was counted as a separate patient. Repeated infu-
sions of levosimendan were calculated on a yearly basis
between January 1 and December 31, unless the same
PICU admission continued into the following year.
Levosimendan infusion was usually started with a
bolus dose of 12 to 24 mcg/kg over 10 min followed by
0.1 mcg/kg/min infusion. The dose was increased slowly
to 0.2 mcg/kg/min and usually the total duration of the
infusion was 24 hours, but in some patients infusion
was continued for up to 48 hours. The bolus dose was
omitted in some of the unstable hypotensive patients as
recommended in the adult literature [12]. Levosimendan
was coadministered in different combinations with the
other vasoactive drugs including: epinephrine, norepi-
nephrine, milrinone, vasopressin and inhaled nitric
oxide.
A survey of physicians was carried out by questionnaire
at the end of August 2010, before the results of the levo-
simendan audit in our hospital were presented by the
author. A questionnaire was sent via email to all the spe-
cialists of anaesthesiology, cardiology and cardiac surgery
(Additional file 1). The questionnaire consisted of 10
multiple choice questions and was specially designed to
determine the indications, patient groups, possible
adverse events and perceptions of the effects of levosi-
mendan infusions the physicians could recall.
Results
During the nine year study period a total of 484 infu-
sions were administered to 293 patients during 369
PICU admissions. The median age of the children at the
time of levosimendan administration was 0.4 years
(range: 4 hours - 21.1 years). Moreover, 65% of the
patients were younger than one year of age (Table 1). A
small majority of the patients were boys 197 (53.3%).
A majority of levosimendan infusions were administered
to children undergoing cardiac surgery (n = 210, 72%) and
14% of levosimendan infusions were respectively given to
children either with cardiomyopathy (n = 41) or who had
decompensated heart failure (n = 42). In the cardiomyopa-
thy group 36 patients had dilated, two restrictive, one
obstructive cardiomyopathy and in two patients the etiol-
ogy was undefined. Of those children with decompensated
heart failure, 32 had congenital heart disease that had not
been operated on during the PICU admission, five had
Table 1 Ages of the children who received levosimendan
infusion during 369 PICU admissions
Age Number Percentage
<1 months 89 24.12
1-12 months 151 40.92
1-4 years 73 19.78
5-12 years 31 8.40
>12 years 25 6.78
Median (year) 0.40
Interquartile range (year) 0.09- 2.08
Range 4 hours - 21.1 years
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had other etiologies.
The annual increase in levosimendan use was related
to cardiac surgery patients (Figure 1). Of all the 331
infusions given to children undergoing cardiac surgery,
25% were initiated in the OR. A trend towards the
initiation of levosimendan infusion before surgery in the
PICU or after induction of anesthesia has occurred in
recent years. The most common defects in children who
had undergone cardiac surgery and who received levosi-
mendan, are shown in table 2. Twenty of the 36 patients
with hypoplastic left heart syndrome (55.6%) were neo-
nates undergoing the Norwood 1 operation.
Eighty-nine out of the 293 patients (30.4%) received
repeated doses of levosimendan (up to 11 infusions). Of
the repeated doses 66.3% were administered to cardiac
surgery patients, 24.7% to cardiomyopathy and 9.0% to
cardiac failure patients. The median dosing interval was
9.1 days (range 2.7- 264.1 days).
During the nine year study period, 26 patients (0.9% of
the total number of operations.n = 2566) required
mechanical cardiopulmonary support in the postopera-
tive period. All except one of the 24 patients [16 patients
in left or right ventricular assist device (LVAD, RVAD),
seven in extracorporeal membrane oxygenation (ECMO)
and three in intraaortic balloon pump (IABP)] received
levosimendan before or after placement onto the
mechanical assist device to enhance weaning from the
device or support the right ventricle during the support
period. Seventeen of the 24 patients (70.1%) were suc-
cessfully weaned from the device. Of the patients with
cardiomyopathy one patient was treated by ECMO, one
by LVAD and eight by a long term support device Berlin
Heart VAD. All of them also received levosimendan infu-
sion during the mechanical support. Six of the eight
patients with cardiomyopathy were successfully bridged
to heart transplantation after seven to 189 days support
by the Berlin Heart VAD.
Of the 293 children who received levosimendan infu-
sions, 36 (12.4%) died in the PICU. Twenty-two (10.5%)
children of the cardiac surgery group died compared to
the overall mortality of 2.3% for the children undergoing
cardiac surgery during the same study period.
Eighteen of the 29 (62.1%) anesthesiologist/intensivists,
cardiologists and cardiac surgeons to whom the survey
was emailed responded. There were no differences in the
answers from the different specialists. Levosimendan was
considered to be safe and efficacious for use in children
based on the extensive experimental and adult patient
studies by 88.9% of the respondents. However, it was
Figure 1 The etiology of 293 patients administered with levosimendan infusion.
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from the few existing studies done in children to warrant
the routine use of levosimendan. The most common
indication for the use of levosimendan (94%) reported by
the respondents was when other inotropic agents were
insufficient to maintain stable hemodynamics. Levosi-
mendan was especially used in children with cardiomyo-
pathy (100%) or with low cardiac output syndrome
(94%). Levosimendan infusions were well tolerated, only
hypotension (62.1%) or tachycardia (27.8%) occurred in
the beginning of the infusion or no adverse events
(27.8%) were recalled by the physicians. According to the
survey 89% of the physicians thought that levosimendan
administration had postponed the need for the mechani-
cal assist device in some children with dilated cardiomyo-
pathy. Moreover, 44% of respondents thought that the
mechanical support had been totally avoided in some
patients undergoing cardiac surgery after receiving levosi-
mendan. Eleven out of 18 physicians (61.1%) thought that
levosimendan treatment had saved the lives of some chil-
dren when the other treatments had failed.
Discussion
Levosimendan is the best investigated inotropic drug in
adults with more controlled clinical data for it than any
other inotropic drug [1]. However, reported pediatric
experience and randomized levosimendan trials in chil-
dren are few in number [3,11]. This study is the largest
published study on levosimendan use in children to date,
with data on 484 levosimendan infusions delivered to 293
patients. The perioperative use of levosimendan had been
steadily increasing over the years. The prevalent percep-
tions of the physicians who responded were that levosi-
mendan may have postponed or have reduced the need
of mechanical cardiac support in children with cardio-
myopathy or who were undergoing cardiac surgery.
Nevertheless, this perception remains to be proven in
randomized controlled studies.
There is no unequivocal answer as to why our institu-
tion uses levosimendan more widely than in other com-
parable pediatric cardiac centers. Similar to that described
in some case reports published, we have had some miracu-
lous recoveries of patients after the initiation of levosimen-
dan infusion [10,11]. Based on some preliminary studies in
our institution and mostly involving adults, the adminis-
tration of levosimendan has become one of the standard
regimes in children with: failing ventricular function or for
proactive use to facilitate weaning from cardiopulmonary
bypass in children who are undergoing cardiac surgery
[3,13]. Levosimendan has been included in the expensive
drugs list in our hospital, but has been readily available
when indicated without any special authorization.
Levosimendan use in children with cardiomyopathy or
decompensated failure remained at the same level during
the nine year period. The observed increase in levosimen-
dan use was related to cardiac surgery patients. A trend
towards the initiation of levosimendan infusion in the
PICU before surgery or after induction of anesthesia has
occurred in recent years. This trend is based on the adult
cardiac surgery experience that the full clinical potential
of levosimendan is best realized when it is used in a pro-
phylactic manner: i.e. started before CPB commences
and before the onset of surgical ischemia in patients at
risk of developing low-output syndrome after CPB
[12,14,15]. In the only randomised and double-blind trial
in children undergoing cardiac surgery, levosimendan
was shown to be as efficacious as milrinone, although,
levosimendan was started after the release of the aortic
cross clamp with a relatively low dose 0.05 mcg/kg/min
and without an initial bolus dose [6].
D u r i n gt h en i n ey e a rs t u d yperiod the use of postcar-
diotomy mechanical support (0.9%) was fairly low in our
institution compared to that reported in the pediatric lit-
erature [16]. In our institution levosimendan was
initiated proactively in the OR or when the weaning from
CPB failed at the first attempt for many of the higher risk
cases. Most likely the threshold as to when to switch
from inotropic support to mechanical support is higher
than in many other pediatric cardiac centers. Therefore,
it is impossible to conclude whether levosimendan treat-
ment had any effect on the use of postcardiotomy
mechanical support.
Mortality in children who received levosimendan infu-
sions after cardiac surgery (11%) was higher than the
overall mortality of 2.3% after cardiac surgery during the
Table 2 The most common etiologies of the 210 children
who were undergoing congenital heart surgery who
received levosimendan infusions either in the OR or in
the PICU
Number
Hypoplastic left heart syndrome 36
Transposition of great arteries 24
Atrioventricular septal defect 18
Univentricular heart (other) 15
Aortic stenosis 13
Pulmonary atresia 11
Ventricular septal defect 11
Tetralogy of Fallot 10
Interrupted aortic arch 9
Truncus arteriosus 8
ALCAPA 7
Double outlet right ventricle 7
Coarctation of the aorta 7
Ebstein anomaly 6
other 28
ALCAPA, anomalous left coronary artery from pulmonary artery.
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tered to the high risk patients and after the other ino-
tropic agents were found to be insufficient to maintain
stable hemodynamics. Therefore, a higher mortality rate
similar to that found for earlier pediatric levosimendan
studies including those on high risk patients was to be
expected [4,7,9].
The perception shared by many respondents, that
repeated levosimendan infusions may have postponed
the need of mechanical cardiac support in children with
cardiomyopathy, remains to be proven in future studies.
A tt h em o m e n tw eh a v en od a t ao nt h ee f f e c t so f
repeated levosimendan infusions on the ejection fraction
or any laboratory parameters such as brain natriuretic
peptide (BNP) in patients with cardiomyopathy. In the
placebo control study carried out by Parissis et al. serial
levosimendan infusion of adult patients with decompen-
sated heart failure significantly improved the left ventri-
cular performance and decreased BNP and immune
activation [17].
An important shortcoming of our study is that it is a
retrospective study. The number of physicians who
responded to the questionnaire (62%) was somewhat low,
because many were still on summer vacation during the
survey and consequently never completed it. We did not
use any specific risk classification for patients in cardiac
failure. Therefore levosimendan infusion was started
based on the clinical findings of the cardiac failure
patient including poor hemodynamic profile, metabolic
acidosis, poor tissue perfusion, oliguria and rising serum
lactate levels despite escalating inotropic support. The
information regarding other vasoactive drugs that these
patients were receiving prior to introduction of levosi-
mendan and information on the impact of levosimendan
on discontinuation of other vasoactive drugs, would have
been extremely informative. Unfortunately, the patient
data in this study are heterogeneous, and indications and
timing about when to use levosimendan has been vari-
able. There is a lack of randomized controlled studies on
the use of levosimendan in children, thus our clinical
practice and perceptions of the effects of levosimendan
on the clinical outcome serves as a good example of insti-
tutional based medicine rather than empirical evidence
based medicine.
Conclusions
In the institution in which levosimendan is widely used,
many physicians believe that its use could have an effect
on the extent of mechanical support needed in children
undergoing cardiac surgery or decompensated heart fail-
ure, although there is still a lack of good evidence
to support this perception. Randomized and controlled
s t u d i e so nt h eu s eo fl e v o s i m e n d a ni nc h i l d r e na r e
warranted.
Additional material
Additional file 1: Levosimendan questionnaire. A multiple choice
questionnaire for physicians.
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